NanaBis (NanoCelle CBD/THC)

CLINICAL TRIAL

The buccal administration of a Cannabis sativa L./Cannabis indica L. extract as an adjunct to opioid analgesia for the management of intractable pain in patients diagnosed with advanced cancer: a safety, tolerability and exploratory end-point pilot study

FORMULATION

NanaBisTM is an investigative new product containing 1:1 ratio of Cannabidiol (CBD) and delta-9-trethydrocannabinol (THC), in a sub-micron spray applied to the oro-buccal membrane.

DATE of HREC approval

16 June 2017

HREC

Northern Sydney Local Health District

HREC Approval ID

HREC/16/HAWKE/496

CTN

CT-2017-CTN-02369-1 v3

ANZCTR

ACTRN12617001480370

STUDY SITE

Royal North Shore Hospital, Oncology Department

STATUS

Completed